Zydus receives final approval from the USFDA for Cyclophosphamide Capsules USP, 25 mg and 50 mg

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Cyclophosphamide Capsules USP, 25 mg and 50 mg (USRLD: Cyclophosphamide Capsules, 25 mg and 50 mg).

Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cells. It treats lymphoma, myeloma, leukemia, breast cancer and ovarian cancer. The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Cyclophosphamide Capsules USP, 25 mg and 50 mg had annual sales of USD 6 mn in the United States (IQVIA MAT October,2023).

The group now has 383 approvals and has so far filed over 448* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 646.20 as compared to the previous close of Rs. 643.50. The total number of shares traded during the day was 16151 in over 1041 trades.

The stock hit an intraday high of Rs. 651.05 and intraday low of 642.45. The net turnover during the day was Rs. 10439238.00.

(*as of 30th September 2023)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 USFDA Approval CyclophosphamideCapsules